Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biodyn Share News (OBD)

Share Price Information for Oxford Biodyn (OBD)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 8.00
Bid: 8.00
Ask: 8.48
Change: -0.10 (-1.23%)
Spread: 0.48 (6.00%)
Open: 8.20
High: 8.20
Low: 8.00
Prev. Close: 8.10
OBD Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: K3 Capital upbeat; Morses sinks after warning

Tue, 21st Jun 2022 11:45

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

----------

AIM - WINNERS

----------

K3 Capital Group PLC, up 10% at 258.36 pence, 12-month range 205.00p-380.00p. The professional advisory services firm says its annual results are likely to exceed market expectations. K3 says for the year ended May 31, revenue is expected to grow by around 43% to GBP77.5 million, from GBP47.2 million the year before. Adjusted earnings before interest, tax, depreciation and amortisation are expected to be 24% higher at GBP19.5 million from GBP15.7 million. The figures exceed market expectations, which according to Numis sit at GBP63.5 million for revenue and GBP18.2 million in Ebitda.

----------

Oxford Biodynamics PLC, up 8.0% at 17.55p, 12-month range 15.50p-62.80p. Shares in biotech firm move off 12-month lows after its checkpoint inhibitor response test becomes available in the UK. The EpiSwitch CiRT blood test predicts a patient's likely response to immune checkpoint inhibitor therapies, with high levels of sensitivity, specificity, accuracy and negative predictive value across 15 cancer indications where ICI treatments are approved. The test is now available to private physicians in the UK online. Oxford says the appeal of the test for the UK's National Health Service, given the high rates of inefficacy of ICI treatments, and their high costs.

----------

Midatech Pharma PLC, up 7.8% at 9.43p, 12-month range 8.16p-38.00p. The biotechnology company receives Orphan Medicinal Product designation from the European Medicines Agency for the development programme for MTX110. Explains that the designation offers protocol development assistance, a reduction in fees and market exclusivity upon the successful approval of the drug.

----------

AIM - LOSERS

----------

Morses Club PLC, down 24% at 7.91p, 12-month range 4.50p-95.00p. The doorstep lender warns that an increase in complaints could badly affect its trading performance for the first half of its financial year. Morses says that its home collected credit division has seen a rise in complaints submitted by claims management firms, leading to claim volumes returning to the level seen in February. Should this level be sustained, Morses expects the cost of the complaints could hurt its trading performance for the six months ending August 31.

----------

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
21 May 2019 16:05

UK Earnings, Trading Statements Calendar - Next 7 Days

Wednesday 22 May Marks & Spencer GroupFull Year ResultsRoyal MailFull Year Year Year

Read more
3 May 2019 14:19

Oxford BioDynamics Chosen To Join ALS Biomarker Study

LONDON (Alliance News) - Oxford Biodynamics PLC said on Friday it has joined the REFINE-ALS study, designed to identify specific biomarkers in people with amyotrophic lateral sclerosis.The

Read more
23 Apr 2019 10:33

Three AIM firms celebrate Queen's Award for Enterprise wins

(Sharecast News) - Three firms trading on London's AIM market were celebrating wins in the Queen's Award for Enterprise on Tuesday, with Inspiration Healthcare, Ergomed and Oxford BioDynamics all picking up the accolades.

Read more
5 Apr 2019 11:25

Oxford BioDynamics Appoints Non-Executive Director As Interim Chair

LONDON (Alliance News) - Oxford BioDynamics PLC said on Friday it has promoted Non-Executive Director Steven Wiggle as interim chair with immediate effect.Wiggle will be replacing David who

Read more
2 Apr 2019 12:08

Oxford BioDynamics Launches US Business With New Commerical Head

LONDON (Alliance News) - Biotechnology firm Oxford BioDynamics PLC said Tuesday it has established a US subsidiary and appointed a commercial head for the country.In line with its strategy

Read more
19 Mar 2019 11:54

Oxford BioDynamics EpiSwitch Test Included In Cancer Screening Study

LONDON (Alliance News) - Oxford BioDynamics PLC on Tuesday said it has signed an agreement for its EpiSwitch test to be used by Imperial College London in a prostate cancer screening College is to

Read more
19 Mar 2019 11:43

Oxford BioDynamics biomarker to be used in prostate cancer test trial

(Sharecast News) - Oxford BioDynamics announced on Tuesday that it has signed an agreement with Imperial College London, to utilise its latest 'EpiSwitch' biomarker signature for the blood-based diagnosis of prostate cancer in the 'PROSTAGRAM' trial.

Read more
15 Feb 2019 14:55

DIRECTOR DEALINGS: Oxford BioDynamics Non-Exec's Associate Buys Shares

LONDON (Alliance News) - Oxford BioDynamics PLC on Friday said that the Vulpie Life Sciences Fund, controlled by Non-Executive Director Steven Diggle, purchased nearly GBP37,000 in stock over two

Read more
11 Jan 2019 10:21

Oxford Biodynamics Chair And Long-Serving Non-Exec To Stand Down

LONDON (Alliance News) - Biotechnology company Oxford Biodynamics PLC said Friday Chair David Williams and Non-Executive Director Alison Kibble will stand down later in 2019.Williams - 2016

Read more
11 Dec 2018 11:47

Oxford BioDynamics Annual Loss Narrows On Lower Costs

LONDON (Alliance News) - Oxford BioDynamics PLC on Tuesday reported a sharply narrowed annual loss due to absence of initial public offering related costs.For the year ended September 30, a

Read more
29 Aug 2018 17:03

GL Healthcare Holds 5% Oxford Biodynamics Stake After Deal (ALLISS)

LONDON (Alliance News) - Oxford Biodynamics PLC said Wednesday that GL Healthcare Investment LP holds a 5.1% stake in the biotechnology company after a transaction on Tuesday.GL holding the

Read more
22 Aug 2018 10:26

Chinese Investor Chooses Oxford BioDynamics As First European Partner (ALLISS)

LONDON (Alliance News) - Oxford BioDynamics PLC on Wednesday said a Chinese investment management firm has invested GBP9.8 million in the company.GL Capital Group, which focuses on firms, a

Read more
22 Aug 2018 08:39

Oxford BioDynamics sets sights on China following GL investment

(Sharecast News) - AIM-listed biotechnology company Oxford BioDynamics has launched a strategic partnership with GL Capital, a Chinese healthcare-focused investment group.

Read more
22 May 2018 14:06

Oxford BioDynamics Interim Loss Narrows On Increased Revenue

LONDON (Alliance News) - Oxford BioDynamics PLC on Tuesday reported a narrowed first half loss on the back of increase in revenue.The epigenetic biomarker developer recorded a pretax loss a

Read more
15 May 2018 16:10

UK Earnings, Trading Statements Calendar - Next 7 Days

Wednesday 16 May C&C GroupFull Year ResultsBurberry GroupFull Year & Year Year 17

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.